Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics

Executive Summary

Supporters of narrowing opioid drugs’ non-cancer pain indication tell FDA that pain patients often suffer the consequences of addiction and misuse.


Related Content

Purdue Petition Seeks FDA Commitment To “Adapted” Studies For OxyContin Generics
FDA’s Parks Expands REMS Portfolio With Move To ODE II Deputy Slot
Strategy Of A Corporate Split: An Interview With Mallinckrodt’s Mark Trudeau and Matt Harbaugh
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting
Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon
Opioid Abuse-Deterrent Formulations Could Become Prerequisite To Approval
Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant
Citizen Petition Seeks Limited Opioid Drug Indication To Curb Overuse And Abuse
Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts